Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Diluted EPS of $2.33 per share for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.33 | +206.9% |
| 2024 | -$2.18 | +38.1% |
| 2023 | -$3.52 | +62.2% |
| 2022 | -$9.30 | -29.2% |
| 2021 | -$7.20 | +3.5% |
| 2020 | -$7.46 | +8.0% |
| 2019 | -$8.11 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.84 | +311.5% | +460.8% |
| June 30, 2025 | -$0.51 | -292.3% | -15.9% |
| March 31, 2025 | -$0.44 | +15.4% | +49.4% |
| September 30, 2024 | -$0.87 | -175.7% | -569.2% |
| June 30, 2024 | -$0.13 | +94.1% | +75.0% |
| March 31, 2024 | -$0.52 | +62.9% | -145.2% |
| September 30, 2023 | $1.15 | +134.6% | +152.0% |
| June 30, 2023 | -$2.21 | +3.5% | -57.9% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +206.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s diluted eps has grown by 128.7% (from $8.11 per share (loss) to $2.33 per share).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: